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Abstract
Background: The oral anticoagulant therapy - provided to prevent thrombosis - is known to be associated with
substantial avoidable hospitalization. Improving the quality of the oral anticoagulant therapy could avoid drug
related hospitalizations. Therefore, this study compared the patient outcomes between Dutch anticoagulant clinic
(AC) regions taking the variation in chronic care management into account in order to explore whether chronic
care management elements could improve the quality of oral anticoagulant therapy.
Methods: Two data sources were combined. The first source was a questionnaire that was send to all ACs in the
Netherlands in 2008 (response = 100%) to identify the application of chronic care management elements in the
AC regions. The Chronic Care Model of Wagner was used to make the concept of chronic care management
operational. The second source was the report of the Dutch National Network of ACs which contains patient
outcomes of the ACs.
Results: Patient outcomes achieved by the ACs were good, yet differences existed; for instance the percentage of
patients in the appropriate therapeutic ranges varied from 67 to 87% between AC regions. Moreover, differences
existed in the use of chronic care management elements of the chronic care model, for example 12% of the ACs
had multidisciplinary meetings and 58% of the ACs had formal agreements with at least one hospital within their
region. Patient outcomes were significantly associated with patient orientation and the number of specialized
nurses versus doctors (p-values < 0.05). Furthermore, the overall extent to which chronic care management
elements were applied was positively associated with patient outcomes (p-values < 0.05).
Conclusions: Substantial differences in the patient outcomes as well as chronic care management of oral
anticoagulant therapy existed. Since our results showed a positive association between overall application of
chronic care management and patient outcomes, additional research is needed to fully understand the working
mechanism of chronic care management.
Background
Oral anticoagulant therapy (OAT) is one of the major
causes of drug related avoidable hospitalizations [1,2].
Oral anticoagulants - chronically used to prevent throm-
bosis - have a narrow therapeutic range to balance the
risk of haemorrhage and thrombosis [3]. Moreover, this
balance is easily influenced by various factors, such as
co-medication or dosage modification [4,5]. As a
consequence, many health care professionals influence
the effect of OAT for instance when subscribing co-
medication [6]. Therefore, the management of OAT is
paramount to prevent adverse events (e.g. haemorrhage
or thrombosis) [7].
A broad line of research studying the initiatives to
improve the management of chronic care has evolved in
the last decade. Terms used for these initiatives are case
management, shared care, and integrated care, but perhaps
best known from an international perspective are the
Chronic Care Model (CCM) and disease management,
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both of which were introduced first in the U.S. [7,8]. These
models are implemented to improve chronic care manage-
ment to realize patient-centered care in which problems
like fragmentation, guideline inadherence and restricted
self-management are limited.
With respect to the OAT, differences in chronic care
management exist between countries. Chronic care
management is provided by routine medical care (for
instance in France and US) or specialized anticoagu-
lant clinics (ACs) (for instance in Italy and the Nether-
lands) [9,10]. In particular, in the Netherlands,
intensive follow-up of patients using oral anticoagu-
lants is provided by 61 specialized anticoagulant clinics
(ACs) at the time of our study [11]. After subscription
of the oral anticoagulants by the primary physician or
specialist, all patients are followed by the ACs at least
every 6 weeks. The AC’s specialized nurse and/or spe-
cialized physician advice on medication doses based on
their gathered monitoring results. So far, previous stu-
dies have shown that ACs achieve better patient out-
comes than routine medical care [3,9,12]. However,
influences of differences in chronic care management
between ACs regions on patient outcomes of OAT are
unclear.
Since chronic care management improves patient out-
comes for certain diseases [8,13,14], this study will com-
pare the patient outcomes between AC regions taking
the variation in chronic care management into account.
First, we will describe differences in patient outcomes
between the AC regions for patients chronically receiv-
ing OAT. Second, we will describe the differences in
chronic care management between these AC regions.
Finally, we will study the association between the varia-
tion in patient outcomes and the differences in chronic
care management in order to reveal suggestions for
quality improvement.
Methods
Data used in this study derived from two sources which
were combined. The first source is a questionnaire that
was send to all ACs in the Netherlands in 2008
(response = 100%). The second source is the publicly
available year report of the Dutch National Network of
ACs (FNT). From these reports, the patient outcomes -
which are the results of two cross-sectional measure-
ments assessed by all ACs at two identical moments in
the year - were derived.
Two relatively new ACs were excluded for this study,
because their patients only include self-management
patients, making comparison incorrect. The remaining 59
ACs in the Netherlands take care of more than 375.000
OAT patients users in 2008 [15], including about 99%
extramural thrombosis care in the Netherlands.
Patient outcomes
The International Normalized Ratio (INR) is used as
intermediate outcome for the quality of care. The INR - a
standardized transformation of the prothrombin time to
assess the degree of anticoagulation [3]- is used by the
ACs to determine the needed dosage of oral anticoagu-
lants to correct the prothrombin time. The optimal target
range of the INR for patients depends on the type of indi-
cation [3] and is differentiated to two indication groups
by the Dutch National Network of ACs, i.e. low intensity
group with INR 2.5-3.5 and high intensity group with
INR 3.0-4.0. We used three different measures of the
INR as patient outcome. The first indicator is the percen-
tage of patients within the target range of the INR.
Recently, the therapeutic range (a broader range includ-
ing 0.5 points below the target ranges) is used besides the
target range, since it is assumed to be a better measure
for the quality of care considering the OAT [15]. There-
fore, the percentage of long-term patients within the
therapeutic range is used as second outcome variable.
Additionally, the percentage of patients below the thera-
peutic range will be used as a quality indicator. This out-
come is selected because it was recently shown that the
relative risk of adverse events below an INR of 2 is higher
than an INR of 3 to 5 [16,17]. In addition, we attempted
to use the number of severe complications which is
restricted to severe haemorrhages as quality indicator.
However, we excluded this outcome measure since the
reliability of the reported results considering this measure
are questioned by the Dutch National Network of ACs
and the authors of this paper [15].
Chronic care management
The Chronic Care Model (CCM) of Wagner is used to
identify elements of chronic care management. The
CCM captures six components which all conceive ele-
ments on practice level to structure chronic care such
as software applications for decision support or educa-
tion for self management support [7]. The CCM ele-
ments that were included in our questionnaire were
selected and made measurable based on the literature
and the expert opinion of about twenty professionals
working in the thrombosis field. The characteristics of
the chronic care management identified with the ques-
tionnaire are described by five components of the CCM
namely: health care organization (i.e. the organizations’
focus on chronic care for instance by incident reporting
system); self-management support (i.e. supporting
patients to manage their condition for instance by self-
management education); delivery system design (i.e. the
organization of providing care such as other roles/
teams); decision support (i.e. integration of evidence
based clinical guidelines into practice for example by a
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reminder system) and clinical information system (i.e.
systems that support the information exchange) (table 1).
The identified chronic care management elements
applied by the AC regions are hypothesized to improve
the chronic care management and as a consequence the
patient outcomes as suggested by the CCM. Although
the sixth component of the CCM - community resources
and policies - is relevant for chronic care management
(e.g. legislation to allow self management), this is not
taken into account in this study because the variation in
this element differs on another level than the level of ana-
lysis of this study, i.e. the AC regions.
Data analysis
A combination of descriptive analysis and regression
analysis was used to perform this study. The variation in
patient outcomes and the elements of chronic care man-
agement were studied with descriptive analyses. Subse-
quently, data were subjected to regression analysis to
identify to what extent the differences in patient out-
comes are associated with chronic care management
activities. The regression analysis were controlled for the
type of reagent (the use of Innovin versus other reagent)
since previous research showed that use of Innovin may
systematically give different results on the measured
INR [18]. The associations between the use of CCM and
quality of care are studied in two different ways.
First, we studied the use of each separate element of
the CCM and its association with quality of care. Items
of CCM were excluded from the regression analysis if
the variation was too small (i.e. less than 10%).
Second, we constructed a scale representing the use of
all elements of the CCM. Since Wagner et al. argue that
the use of more elements of CCM is associated with a
stronger improvement of the quality of care, this may be
a more appropriate way to study the associations of
interest [19]. The CCM variables were transformed into
a z-distribution to aggregate the items to the related
components of the CCM by computing the mean. Sub-
sequently, we determined the relative use of the compo-
nents of the CCM. The components of Wagner were
included as a score in the construct when its use was
more than 0 on the z-scale, indicating that it was used
more than average by the AC region. The ensuing scale
represented the number of CCM components which are
used more by a thrombosis clinic than by other throm-
bosis clinics. It can be interpreted as a count of the rela-
tive use of the CCM components: the higher the score,
the more CCM components are used.
Results
Quality of care
Results showed that the percentages of patients within
and below the therapeutic range varied. Figure 1
visualizes these patient outcomes for each AC region.
The number of patients within the appropriate therapeu-
tic range varied between AC regions from 66.7% to 86.8%
(mean = 76.8; sd = 5.1). Furthermore, the number of
patients below the appropriate therapeutic range varied
from 1.8% to 13.4% (mean = 7.8; sd: 2.6) of the patients
between the AC regions. The number of patients within
the appropriate target range varied from 48.5% to 70.7%
(mean = 59.1; sd = 5.8). This implies that the chance to
be in the correct target or therapeutic range can be 20%
higher in one AC region compared to another.
Table 1 Differences between AC regions in chronic care






Quality improvement system (none/IKA or VIM/
both)
1/10/48
Insight in telephonic waiting times(proxy patient
orientation)
24
Accreditation (no/once/more than once) 14/13/32
Self management support
Percentage of self management patients 5.0 (4.9)
Self-management support with webbased
application
15
Frequency of self management control by AC 3.8 (1.4)
Delivery system (re)design
Regional multidisciplinary meeting 7
Specialized nurses versus doctors 8.7 (11.3)
Decision support
Formal agreements with hospitals 34
Software used for dosage advice 57
Info to AC about prescribed interacting drugs
(no. always and mean (scale never-always: 0-3))
Info from the pharmacist about starting 28 2.4 (0.6)
Info from the dispensing GP about starting 11 1.5 (1.0)
Info from the pharmacist about change/
discontinue
12 1.6 (1.0)
Info from the dispensing GP about change/
discontinue
4 1.0 (1.0)




Communication medium (telephone or other
with INR > 8)
44
Webbased patient information for dosage advice 11
GP (general practitioner), IKA (system to report ideas, complaints and
deviations), INR (International normalized ratio), VIM (safe reporting of
incidents).
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Chronic care management
The differences in chronic care management between
the AC regions, categorized to components of the CCM,
are shown in table 1. All ACs reported to have a quality
manager and almost all a client board which is manda-
tory in the Netherlands. Differences are shown in the
component ‘health care organization’ considering quality
improvement system and patient orientation. In addi-
tion, more than half of the ACs have been accredited
more than once which implies consistency of their qual-
ity of care.
The component ‘delivery system design’ showed that 7
of the 59 thrombosis clinics reported to participate in
regional multidisciplinary meetings in 2007. The ratio of
specialized nurses versus doctors - measured in full-time
equivalent - showed a mean ratio of 8.7. This implies
that the average number of full-time equivalents (FTE’s)
of the specialized nurses is 8.7 times higher than the
number of FTE’s of the doctors. Especially the number
of specialized nurses differed; ranging from 0 specialized
nurses (which is the case for 9 ACs) to 15 specialized
nurses working at the AC.
Furthermore, the component ‘decision support’ was
applied in most AC regions (n = 57) by using a software
system which propose dosage advices that could give
the doctors a direction. Formal agreements between the
hospital and the ACs are less frequently reported; 34 of
the ACs had formal agreements with at least one hospi-
tal of their region.
In addition, the characteristics of the component ‘clin-
ical information system’ showed that 44 of the ACs
always contact the physician about a INR above 8.0
(which is advised by the Dutch National Network of
ACs), 11 of the ACs use a web based dosage system,
less than half of the ACs are always informed about
interacting drugs by the pharmacist.
The association between quality of care and CCM
First, the associations between the individual chronic care
elements and the quality of care were studied (table 2).
These regression analyses were corrected for the type of
reagent (Innovin or other reagent) which was signifi-
cantly associated with quality of care (p = 0.008) and is
likely to distort the associations we are interested in. The
analysis showed that the variables ‘insight in waiting
times’ (as proxy for patient orientation) and the ratio
‘specialized nurses versus doctors’ were associated with a
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Figure 1 Patient outcomes on the therapeutic range (N = 57). Blue bar shows the percentage of patients within the appropriate therapeutic
range per AC region. Red bar shows the percentage of patients below the appropriate therapeutic range per AC region.
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therapeutic range. Furthermore, only the ratio ‘specia-
lized nurses versus doctors’ is statistically significant
associated with the number of patients within the target
range. No statistically significant associations were
observed with the number of patients below the thera-
peutic range.
Second, the association between the overall use of
chronic care management and the patient outcomes was
studied. The analysis showed that the use of more CCM
components was positively associated with better patient
outcomes since the number of components was asso-
ciated with a higher percentage of patients within the
therapeutic range (B = 1.248; p = 0.017) and target
range (B = 1.358; p = 0.024). The use of more CCM
components was not significantly associated with the
percentage of patients below the therapeutic range (B =
-0.485; p = 0.073).
Discussion
This study was performed to identify the differences in
patient outcomes and their relationship with chronic
care management of OAT. Although the Netherlands
manage OAT with specialized clinics as is recom-
mended by the ACCP guidelines and achieve a good
quality of care according to the criteria of the Dutch
National Network of ACs, remarkable differences exist.
The percentage of patients in the correct INR ranges
differed with more than 20%-point. Furthermore, differ-
ences existed in the application of chronic care manage-
ment which was measured with elements based on the
components of the chronic care model (i.e. the health
care organization, self-management support, delivery
system design, decision support and clinical information
system). Two chronic care management elements, i.e.
patient orientation and the ratio of specialized nurses
Table 2 Association between patient outcomes and chronic care management elements categorized by the CCM
elements (N = 57)
Therapeutic range Target range
B p-value B p-value
Health care organization
Client board -3.001 0.304 -3.096 0.359
Quality manager NA NA NA NA
Quality improvement system (none/IKA or VIM/both) 0.901 0.550 1.008 0.562
Insight in telephonic waiting times (proxy patient orientation) 2.524 0.050* 1.883 0.210
Accreditation (no/once/more than once) 1.225 0.124 1.265 0.170
Self management support
Percentage of self management patients 21.450 0.109 8.097 0.604
Self-management support with webbased application -2.583 0.077 -3.103 0.065
Frequency of self management control by AC 0.616 0.198 0.259 0.641
Delivery system (re)design
Regional multidisciplinary meeting -0.255 0.898 -2.135 0.352
Specialized nurses versus doctors 0.131 0.035* 0.166 0.020*
Decision support
Formal agreements with hospitals 0.097 0.941 0.350 0.817
Software used for dosage advice NA NA NA NA
Info to AC about prescribed interacting drugs (no. always and mean (scale never-always: 0-3))
Info from the pharmacist about starting 0.337 0.774 1.396 0.301
Info from the dispensing GP about starting 0.127 0.848 0.921 0.225
Info from the pharmacist about change/discontinue -0.135 0.841 -0.923 0.231
Info from the dispensing GP about change/discontinue -0.276 0.696 0.004 0.996
Information from the hospital (scale slow-fast: 0-10) -0.090 0.893 0.463 0.364
Clinical information systems
Communication medium (telephone or other with INR > 8) 2.437 0.099 2.136 0.213
Webbased patient information for dosage advice 0.346 0.844 -1.303 0.521
GP (general practitioner), IKA (system to report ideas, complaints and deviations), INR (International normalized ratio), NA (not assessed), VIM (safe reporting of
incidents).
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versus doctors, were associated with some patient out-
comes. Moreover, the overall use of chronic care man-
agement elements is positively associated with the
patient outcomes.
To our knowledge, no other comparative study of the
differences on the quality of OAT between regions was
performed on a national level before. It was already
shown in previous research that the quality of OAT pro-
vided by ACs is higher than OAT provided by routine
medical care. For example, Ansell and colleagues
showed that the percentage of patients within the cor-
rect INR ranges and time-in-range is higher in anticoa-
gulant clinics in Spain and Italy than in routine medical
care in France, U.S. and Canada [9]. Our study showed
that differences in quality of OAT exist between ACs
which suggests that even the ACs that already provide a
relatively high quality of care compared with routine
medical care [9], could improve their quality of care.
Furthermore, our results showed differences in the per-
centage patients below the appropriate therapeutic
range (range 1.8% to 13.4%) which should be further
studied as the relative risk for adverse events was sug-
gested to be frequently underestimated [16,17].
The identified differences in chronic care management
offered an opportunity to explore whether these could be
associated with the quality of OAT. Only two chronic care
management elements, i.e. patient orientation and the
ratio of specialized nurses versus doctors, were significantly
associated with patient outcomes while the other elements
were not. It could be hypothesized that patient orientation
and ratio of specialized nurses versus doctors results in
more patient centered care since there is more time spent
per patient and therefore more likely to deliver good care.
However, the data of this study were not specific enough
to test the hypothesis and should be further studied.
Furthermore, we found an association between the use
of more CCM components and better patient outcomes.
This is in line with results of earlier published meta-
analyses of clinical trials [8,13,14], that showed an asso-
ciation between the differences in patient outcomes and
chronic care management. Moreover, our results seem
to confirm that only when more components of the
CCM are used, this will result in better care, while frag-
mentary use of the CCM is unlikely to improve care.
As a consequence, additional insight in the use and
validation of a construct variable for the overall applica-
tion of chronic care management can be useful since
the effect is assumed to be achieved by the combination
of initiatives instead of certain elements. Some instru-
ments were developed to assess the overall extent of
chronic care management, however, the validation of
these instrument are limited and not performed for
OAT [20,21]. A validated instrument to measure the
construct variable would be useful for the professionals
to gather insight in the needs for quality improvement
regarding chronic care management.
Meanwhile, the complexity of the chronic care manage-
ment should be taken into account. Chronic care man-
agement is a social construct which effectiveness is
influenced by more factors than the number of compo-
nents such as the implementation and the integration of
the chronic care model components [22-24]. As chronic
care management seemed to be associated with the
patient outcomes for OAT, more insight in the working
mechanism of chronic care management is needed for
quality improvement. In particular, qualitative studies are
required to explore the association between chronic care
management and patient outcomes in more detail. First,
as chronic care management is complex and underlying
mechanisms are not fully understood, additional qualita-
tive research should be performed to identify the true
needs for quality improvement [23,25]. Second, oral
anticoagulants is not a static field, but is evolving over
time. For instance, two recently developed ACs only
include relatively healthy patients who are performing
self-management. For comparability these ACs were not
included in our analysis. Although these two ACs provide
care to only a relatively small number of patients, this
new organizations could inspire the traditional ACs.
Findings of this study must be interpreted in the light
of several limitations. First, the questionnaire was sent
out by the Health Care Inspectorate (IGZ) which could
cause bias especially social desirability bias which might
have resulted in an underestimation of the association
between chronic care management and patient out-
comes. However, the respondents were aware that this
questionnaire aimed to explore the chronic care man-
agement of OAT on regional level instead of focusing
on the ACs alone. Next, the highly developed documen-
tation of the ACs on national level is in contrast with
the scarcely developed documentation in the clinical set-
ting. As a consequence, gaps exist in the follow-up of
patients (e.g. INR values around hospitalization). These
gaps could not be analysed and controlled for. Thus
they may have affected the association between patient
outcomes and elements of the chronic care model under
study. Furthermore, chronic care management could not
be measured by a validated instrument since these are
not yet available for OAT. However, we selected and
made the elements measurable based on the literature
and the expert opinions of about twenty professionals
working in the thrombosis field. Finally, the analyses of
this study were limited to quality measures reported on
national level. This implies that analyses were performed
on the organization level without case mix corrections
due to a lack of information about patient characteris-
tics such as age and co-morbidity which are not system-
atically registered by the ACs. We only could correct for
Drewes et al. BMC Health Services Research 2011, 11:18
http://www.biomedcentral.com/1472-6963/11/18
Page 6 of 7
the type of reagent, other variations in data gathering
for the reported outcome measures could not be elimi-
nated. Yet, the used data-registration of the Dutch
National Network of ACs on national level is unique
worldwide and gives opportunities to gather more
insight in the needs for quality improvement. Therefore,
AC regions should be stimulated to gain more insight in
the delivery of chronic care management and their influ-
ences on the patient outcomes.
Conclusions
Although, the Netherlands manage oral anticoagulation
therapy (OAT) as is recommended by Ansell and collea-
gues in the ACCP guidelines - i.e. systematic and
coordinated OAT incorporating patient education, sys-
tematic INR testing, tracking, follow-up and good patient
communication, results and dosing decisions by specia-
lized clinics - we observed differences in quality of care
and chronic care management which implies opportunities
to improve the OAT care management. The patient out-
comes seemed to be associated with the overall application
of chronic care management. To get more insight in the
needs of quality improvement, additional data about the
working mechanism of chronic care management with
respect to patient outcomes are required.
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